Skip to main content
. 2023 Jul 3;37(4):1905–1913. doi: 10.21873/invivo.13285

Table II. Details of included cases. Details of 23 reported and two present cases.

graphic file with name in_vivo-37-1909-i0001.jpg

PFS: Progression-free survival; RR: response rate; LN: lymph node; LND: lymph node dissection; F: female, M: male, SD: stable disease; PD: progressive disease; P: partial response; CCRT: concurrent chemoradiotherapy; Ipi: Ipilimumab; Nivo: Nivolumab.